Merkel Cell Carcinoma: New Trends.

Tytuł:: Merkel Cell Carcinoma: New Trends.
Autorzy:: Zwijnenburg EM; Department of Radiation Oncology, Radboudumc, 6525GA Nijmegen, The Netherlands.
Lubeek SFK; Department of Dermatology, Radboudumc, 6525GA Nijmegen, The Netherlands.
Werner JEM; Department of Surgery, Radboudumc, 6525GA Nijmegen, The Netherlands.
Amir AL; Department of Pathology, Radboudumc, 6525GA Nijmegen, The Netherlands.
Weijs WLJ; Department of Maxillofacial Surgery, Radboudumc 6525GA Nijmegen, The Netherlands.
Takes RP; Department of Head and Neck Surgery, Radboudumc, 6525GA Nijmegen, The Netherlands.
Pegge SAH; Department of Radiology and Nuclear Medicine, Radboudumc, 6525GA Nijmegen, The Netherlands.
van Herpen CML; Department of Medical Oncology, Radboudumc, 6525GA Nijmegen, The Netherlands.
Adema GJ; Department of Radiation Oncology, Radboudumc, 6525GA Nijmegen, The Netherlands.
Kaanders JHAM; Department of Radiation Oncology, Radboudumc, 6525GA Nijmegen, The Netherlands.
Źródło:: Cancers [Cancers (Basel)] 2021 Mar 31; Vol. 13 (7). Date of Electronic Publication: 2021 Mar 31.
Typ publikacji:: Journal Article; Review
Język:: English
Imprint Name(s):: Original Publication: Basel, Switzerland : MDPI
References:: J Clin Oncol. 2020 Aug 1;38(22):2476-2487. (PMID: 32324435)
Cell. 2018 Jul 26;174(3):549-563.e19. (PMID: 29937226)
Nat Cell Biol. 2020 May;22(5):603-615. (PMID: 32284543)
EMBO Mol Med. 2020 Nov 6;12(11):e13347. (PMID: 33063436)
Clin Cancer Res. 2014 Apr 1;20(7):1768-78. (PMID: 24526738)
Cancers (Basel). 2020 Feb 28;12(3):. (PMID: 32121063)
Br J Dermatol. 2016 Feb;174(2):273-81. (PMID: 26480031)
Dermatol Surg. 2000 Sep;26(9):853-6. (PMID: 10971559)
Eur J Cancer. 2018 May;94:47-60. (PMID: 29533867)
Ann Surg Oncol. 2018 Oct;25(11):3334-3340. (PMID: 30073600)
Head Neck. 2014 Apr;36(4):571-9. (PMID: 24446426)
Int J Mol Sci. 2019 May 24;20(10):. (PMID: 31137683)
Technol Cancer Res Treat. 2020 Jan-Dec;19:1533033820967454. (PMID: 33084525)
Ann Surg Oncol. 2020 Jun;27(6):1978-1985. (PMID: 32103415)
Lancet Oncol. 2015 Sep;16(9):1049-1060. (PMID: 26206146)
Dermatol Surg. 1995 Aug;21(8):669-83. (PMID: 7633811)
Ann Surg Oncol. 2021 Feb;28(2):1019-1028. (PMID: 32529274)
Head Neck. 2018 Dec;40(12):2704-2713. (PMID: 29934958)
J Am Acad Dermatol. 2017 Jul;77(1):142-148.e1. (PMID: 28495499)
Eur J Surg Oncol. 2021 Feb;47(2):483-485. (PMID: 32736916)
Oncotarget. 2015 Sep 22;6(28):26472-82. (PMID: 26299616)
Cancer Immunol Res. 2019 Oct;7(10):1727-1739. (PMID: 31405946)
J Clin Oncol. 2019 Mar 20;37(9):693-702. (PMID: 30726175)
Surg Oncol. 2018 Mar;27(1):11-17. (PMID: 29549898)
J Surg Oncol. 2020 Aug;122(2):254-262. (PMID: 32297324)
Int J Radiat Oncol Biol Phys. 2011 Aug 1;80(5):1430-5. (PMID: 20708847)
Cancer. 2008 Nov 1;113(9):2549-58. (PMID: 18798233)
J Surg Oncol. 2020 Jun 20;:. (PMID: 32562583)
J Am Acad Dermatol. 2019 Aug;81(2):364-372. (PMID: 30902726)
Laryngoscope. 2021 Mar;131(3):E828-E835. (PMID: 32663337)
Clin Cancer Res. 2017 Jul 15;23(14):3929-3934. (PMID: 28174236)
Arch Surg. 1991 Dec;126(12):1514-9. (PMID: 1842182)
J Natl Cancer Inst. 2016 May 31;108(9):. (PMID: 27245173)
J Eur Acad Dermatol Venereol. 2002 Jan;16(1):82-3. (PMID: 11952300)
Science. 2008 Feb 22;319(5866):1096-100. (PMID: 18202256)
J Immunother Cancer. 2020 Apr;8(1):. (PMID: 32269140)
Cancer. 1983 Sep 15;52(6):1039-43. (PMID: 6349776)
Acta Oncol. 2018 Mar;57(3):320-323. (PMID: 28712323)
Radiother Oncol. 2019 May;134:211-219. (PMID: 31005218)
Head Neck. 2016 Apr;38 Suppl 1:E452-8. (PMID: 25645649)
J Am Acad Dermatol. 2018 Mar;78(3):457-463.e2. (PMID: 29102486)
Int J Radiat Oncol Biol Phys. 2010 Nov 1;78(3):703-9. (PMID: 19939581)
Curr Treat Options Oncol. 2016 Jul;17(7):36. (PMID: 27262710)
Asia Pac J Clin Oncol. 2020 Dec;16(6):312-319. (PMID: 32757453)
JAMA Otolaryngol Head Neck Surg. 2015 Feb;141(2):137-41. (PMID: 25474617)
J Clin Oncol. 2007 Mar 20;25(9):1043-7. (PMID: 17369567)
J Invest Dermatol. 2009 Jan;129(1):248-50. (PMID: 18633441)
Australas J Dermatol. 2020 Feb;61(1):e34-e38. (PMID: 32040877)
Ann Surg Oncol. 2013 Apr;20(4):1365-73. (PMID: 23208132)
J Immunother Cancer. 2020 Sep;8(2):. (PMID: 32948651)
Int J Cancer. 2009 Sep 15;125(6):1250-6. (PMID: 19499548)
Clin Cancer Res. 2019 Oct 1;25(19):5961-5971. (PMID: 31399473)
Cancer. 2015 Sep 15;121(18):3252-60. (PMID: 26038193)
Transplantation. 2002 Jun 15;73(11):1849-50. (PMID: 12085015)
J Invest Dermatol. 2017 Apr;137(4):819-827. (PMID: 27815175)
Int J Radiat Oncol Biol Phys. 2018 Jan 1;100(1):14-15. (PMID: 29254767)
Clin Cancer Res. 2020 Feb 1;26(3):598-607. (PMID: 31582519)
JAMA Dermatol. 2013 Apr;149(4):501-2. (PMID: 23715411)
J Am Acad Dermatol. 2021 Feb;84(2):550-552. (PMID: 33317843)
APMIS. 2013 Aug;121(8):755-69. (PMID: 23781869)
J Surg Oncol. 2018 Jun;117(8):1768-1775. (PMID: 29790179)
Eur J Cancer. 2011 Mar;47(4):579-85. (PMID: 21144740)
Cancers (Basel). 2020 Oct 09;12(10):. (PMID: 33050255)
Ann Surg Oncol. 2014 Oct;21(11):3401-5. (PMID: 25001091)
Cancer Immunol Res. 2015 Oct;3(10):1148-1157. (PMID: 26014098)
J Am Acad Dermatol. 2014 Apr;70(4):637-643. (PMID: 24521828)
Int J Radiat Oncol Biol Phys. 1995 Jul 30;32(5):1401-7. (PMID: 7635780)
Ann Surg Oncol. 2016 Oct;23(11):3572-3578. (PMID: 27251134)
J Clin Oncol. 2011 Mar 10;29(8):1036-41. (PMID: 21300936)
J Clin Microbiol. 2010 May;48(5):1767-70. (PMID: 20181914)
Cancers (Basel). 2014 Jun 27;6(3):1328-50. (PMID: 24978436)
Semin Oncol. 2015 Apr;42(2):347-58. (PMID: 25843739)
Dermatol Surg. 2010 May;36(5):687-93. (PMID: 20384741)
J Am Acad Dermatol. 2011 Nov;65(5):983-90. (PMID: 21641081)
J Immunother Cancer. 2018 May 30;6(1):43. (PMID: 29848371)
Dermatol Surg. 1996 Mar;22(3):262-7. (PMID: 8599738)
JAMA Dermatol. 2016 Sep 1;152(9):1001-7. (PMID: 27248515)
J Immunother Cancer. 2020 May;8(1):. (PMID: 32414862)
Ann Surg Oncol. 2016 Oct;23(11):3564-3571. (PMID: 27198511)
Mod Pathol. 2019 Nov;32(11):1605-1616. (PMID: 31201352)
J Am Acad Dermatol. 2021 Feb;84(2):330-339. (PMID: 32707254)
Nat Rev Clin Oncol. 2018 Dec;15(12):763-776. (PMID: 30287935)
J Immunother Cancer. 2019 Nov 8;7(1):294. (PMID: 31703604)
Ther Adv Med Oncol. 2017 Jul;9(7):451-464. (PMID: 28717398)
J Clin Oncol. 2012 Mar 10;30(8):843-9. (PMID: 22331952)
Eur J Cancer. 2015 Nov;51(16):2396-403. (PMID: 26257075)
Australas Radiol. 2004 Sep;48(3):371-5. (PMID: 15344989)
Clin Cancer Res. 2020 Jun 15;26(12):2777-2782. (PMID: 32047000)
Mol Carcinog. 2020 Jul;59(7):807-821. (PMID: 32219902)
Endocr Pathol. 2020 Mar;31(1):21-32. (PMID: 31808008)
Vaccine. 2012 Feb 8;30(7):1322-9. (PMID: 22210138)
J Invest Dermatol. 2020 Nov;140(11):2146-2156.e4. (PMID: 32304704)
J Am Acad Dermatol. 2018 Mar;78(3):445-454. (PMID: 29229573)
Front Oncol. 2019 Jun 10;9:451. (PMID: 31245285)
J Clin Oncol. 2005 Apr 1;23(10):2300-9. (PMID: 15800320)
Clin Cancer Res. 2013 Oct 1;19(19):5351-60. (PMID: 23922299)
Clin Cancer Res. 2011 Nov 1;17(21):6671-80. (PMID: 21908576)
J Natl Compr Canc Netw. 2018 Jun;16(6):742-774. (PMID: 29891526)
Health Rep. 2017 May 17;28(5):3-11. (PMID: 28513818)
Am J Surg. 2018 Mar;215(3):384-387. (PMID: 29157891)
Int J Cancer. 2019 Aug 15;145(4):1020-1032. (PMID: 30873613)
J Invest Dermatol. 2021 Apr;141(4):903-912.e4. (PMID: 33002502)
J Cutan Pathol. 2010 Jan;37(1):20-7. (PMID: 19638070)
Contributed Indexing:: Keywords: Merkel cell carcinoma; biomarkers; immunotherapy; radiotherapy; surgery
Entry Date(s):: Date Created: 20210403 Latest Revision: 20210413
Update Code:: 20240104
PubMed Central ID:: PMC8036880
DOI:: 10.3390/cancers13071614
PMID:: 33807446
: Czasopismo naukowe

Pełny tekst

Merkel cell carcinoma (MCC) is a rare neuroendocrine tumor of the skin mainly seen in the elderly. Its incidence is rising due to ageing of the population, increased sun exposure, and the use of immunosuppressive medication. Additionally, with the availability of specific immunohistochemical markers, MCC is easier to recognize. Typically, these tumors are rapidly progressive and behave aggressively, emphasizing the need for early detection and prompt diagnostic work-up and start of treatment. In this review, the tumor biology and immunology, current diagnostic and treatment modalities, as well as new and combined therapies for MCC, are discussed. MCC is a very immunogenic tumor which offers good prospects for immunotherapy. Given its rarity, the aggressiveness, and the frail patient population it concerns, MCC should be managed in close collaboration with an experienced multidisciplinary team.

Zaloguj się, aby uzyskać dostęp do pełnego tekstu.

Informacja